Abstract:
:Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 123 patients with intermediate-risk or high-risk SMM were randomly assigned to daratumumab 16 mg/kg intravenously on extended intense (intense), extended intermediate (intermediate), or short dosing schedules. At the prespecified primary analysis (15.8-month median follow-up), the complete response (CR) rates (co-primary endpoint) were 2.4%, 4.9%, and 0% for intense, intermediate, and short dosing, respectively; the co-primary endpoint of CR rate >15% was not met. Progressive disease (PD)/death rates (number of patients who progressed or died divided by total duration of progression-free survival [PFS] in patient-years; co-primary endpoint) for intense, intermediate, and short dosing were 0.055 (80% confidence interval [CI], 0.014-0.096), 0.102 (80% CI, 0.044-0.160), and 0.206 (80% CI, 0.118-0.295), respectively, translating to a median PFS ≥24 months in all arms (P < 0.0001, <0.0001, and =0.0213, respectively). With longer follow-up (median follow-up, 25.9 months), CR rates were 4.9%, 9.8%, and 0% for intense, intermediate, and short dosing, respectively. PD/death rates for intense, intermediate, and short dosing were 0.059 (80% CI, 0.025-0.092), 0.107 (80% CI, 0.058-0.155), and 0.150 (80% CI, 0.089-0.211), respectively, again translating to a median PFS ≥ 24 months in all arms (P < 0.0001 for all arms). Twenty-four-month PFS rates were 89.9% (90% CI, 78.5-95.4%), 82.0% (90% CI, 69.0-89.9%), and 75.3% (90% CI, 61.1-85.0%) for intense, intermediate, and short dosing, respectively. Pharmacokinetic analyses indicated that intense dosing maintained target-saturating trough concentrations in most patients throughout weekly, every-2-week, and every-4-week dosing periods. No new safety signals were observed. These data provide the basis for an ongoing phase 3 study of daratumumab in SMM.
journal_name
Leukemiajournal_title
Leukemiaauthors
Landgren CO,Chari A,Cohen YC,Spencer A,Voorhees P,Estell JA,Sandhu I,Jenner MW,Williams C,Cavo M,van de Donk NWCJ,Beksac M,Moreau P,Goldschmidt H,Kuppens S,Bandekar R,Clemens PL,Neff T,Heuck C,Qi M,Hofmeister CCdoi
10.1038/s41375-020-0718-zsubject
Has Abstractpub_date
2020-07-01 00:00:00pages
1840-1852issue
7eissn
0887-6924issn
1476-5551pii
10.1038/s41375-020-0718-zjournal_volume
34pub_type
杂志文章,多中心研究,随机对照试验相关文献
LEUKEMIA文献大全abstract::The clinical and cell growth characteristics of 11 children with monosomy 7 presenting as preleukemia (eight cases) or acute nonlymphoblastic leukemia (three cases) were studied. Anemia was common to all patients, with nine showing leukocytosis, seven thrombocytopenia, and one thrombocytosis. There was a striking pred...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1987-02-01 00:00:00
abstract::Current MRD studies in T-cell acute lymphoblastic leukemia (T-ALL) mainly use T-cell receptor gamma, delta and SIL-TAL1 gene rearrangements as MRD-PCR targets. However, low frequency or limited diversity of these markers restricts the number of evaluable patients, particularly because two markers are recommended for M...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403263
更新日期:2004-04-01 00:00:00
abstract::In order to assess the proliferative capacity of leukemic subpopulations and to know whether it can be related to the stage of maturation, the expression of two surface antigens identifying distinct steps of leukocyte differentiation (CD15 and CD34) was studied by flow cytometry in correlation with DNA content in 16 c...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1990-01-01 00:00:00
abstract::Large granular lymphocyte leukemia (LGLL) is a rare and chronic lymphoproliferative disorder characterized by the clonal expansion of LGLs. LGLL patients can be asymptomatic or develop cytopenia, mostly neutropenia. Somatic STAT3 and STAT5b mutations have been recently reported in approximately 40% of patients. The ai...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:10.1038/s41375-019-0644-0
更新日期:2020-04-01 00:00:00
abstract::The chromosomal inversion (16)(p13q22), which is associated with the M4-eosinophilia subtype of human acute myeloid leukemia, causes the fusion of two distinct genes. The polypeptide encoded by the chimeric gene, PEBP2p/CBFp-SMMHC, retains the ability to interact with, and dominantly interfere with the function of pro...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401821
更新日期:2000-07-01 00:00:00
abstract::Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML) patients; however, responses to frontline imatinib are variable. The human organic cation transporter 1 (OCT1; SLC22A1) has been reported to be the main influx transporter involved in imatinib uptake into CML cells. Furthermore...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/leu.2015.170
更新日期:2015-10-01 00:00:00
abstract::Therapy-related myelodysplastic syndrome and acute myelogenous leukemia (t-MDS/AML) are serious complications of chemotherapy and radiotherapy for cancer. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may be associated with an increased incidence of these complications. The frequency o...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402631
更新日期:2002-09-01 00:00:00
abstract::The occurrence of leukemia in a gene therapy trial for SCID-X1 has highlighted insertional mutagenesis as an adverse effect. Although retroviral integration near the T-cell acute lymphoblastic leukemia (T-ALL) oncogene LIM-only protein 2 (LMO2) appears to be a common event, it is unclear why LMO2 was preferentially ta...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404563
更新日期:2007-04-01 00:00:00
abstract::As typical disorders of the elderly, myelodysplastic syndromes (MDSs) are relatively unusual in childhood. Nevertheless, up to 17% of cases of pediatric acute myeloid leukemia may have a preleukemic phase. In young patients, the goal of treatment is eradication of the preleukemic malignant clone and reconstitution of ...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1994-05-01 00:00:00
abstract::The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402150
更新日期:2001-08-01 00:00:00
abstract::Remarkable progress has been achieved in the characterization and isolation of primitive hematopoietic stem cells (HSC). HSC represent a very small subset of hematopoietic cells and provide self-renewal, possess differentiation capacity and allow a constant supply of the entire hematopoietic cell spectrum. Until recen...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/sj.leu.2402620
更新日期:2002-09-01 00:00:00
abstract::The molecular events which confer cellular resistance to cytotoxic drugs such as cytosine arabinoside (ara-C) are poorly understood. Nevertheless, in a proportion of patients with acute leukemia, such events will be responsible for the failure of therapy. Mutations which cause ara-C resistance in a chinese hamster ova...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1994-02-01 00:00:00
abstract::We have investigated the effects of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] and several potent vitamin D3 analogs [1,25(OH)2-16-ene-23-yne-D3; 1,25(OH)2-16-ene-23-yne-26,27-F6-D3] on productive infection by human immunodeficiency virus (HIV) in human macrophages. Macrophages derived from the peripheral blood were eithe...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1993-10-01 00:00:00
abstract::To compare the antileukemic efficacy of idarubicin and mitoxantrone in elderly patients with acute myeloid leukemia (AML) and to evaluate the feasibility of autologous transplantation using PBSC after consolidation in those with a good performance status, 160 patients (median age 69 years), with AML at diagnosis, 118 ...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1038/sj.leu.2401445
更新日期:1999-06-01 00:00:00
abstract::Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate ant...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2015.50
更新日期:2015-08-01 00:00:00
abstract::PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively eval...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2016.243
更新日期:2017-03-01 00:00:00
abstract::T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological cancer characterized by skewed epigenetic patterns, raising the possibility of therapeutically targeting epigenetic factors in this disease. Here we report that among different cancer types, epigenetic factor TET1 is highly expressed in T-ALL a...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-020-0864-3
更新日期:2020-05-15 00:00:00
abstract::Inhibitory proteins for Cdks (CKIs) are involved in cell cycle arrest induced by anti-mitotic factors, chemicals, or DNA damage in mammalian cells. High cell density also induces cell cycle arrest with unreplicated genomic DNA even in the presence of mitotic dose of the growth factors, termed contact inhibition. Altho...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1997-04-01 00:00:00
abstract::Despite improved prognosis in acute myelogenous leukaemia (AML) children with Down syndrome (DS), therapy-related toxicity remained a problem. We compared 67 DS patients from study AML-BFM 98 with 51 DS patients of the previous study AML-BFM 93, and the non-DS groups of both studies. Compared to non-DS patients, DS pa...
journal_title:Leukemia
pub_type: 临床试验,杂志文章
doi:10.1038/sj.leu.2403814
更新日期:2005-08-01 00:00:00
abstract::The antimetabolite 6-thioguanine (6-TG) is utilized in the management of acute myelogenous leukemia (AML). Angiogenesis is a possible therapeutic target in hematologic tumors. Thus, we addressed the possibility that 6-TG may also act as an anti-angiogenic molecule. 6-TG inhibited endothelial cell proliferation trigger...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402646
更新日期:2002-08-01 00:00:00
abstract::Deletion and translocation involving the bands 11q14 and 11q21 have been detected in five patients with T cell acute lymphoblastic leukemia (ALL). The breakpoint on chromosome 11 was on the same band as that previously described in some acute nonlymphocytic leukemias: monocytic or myelomocytic. The existence of a new ...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1989-08-01 00:00:00
abstract::We previously reported a strong IL4I1 gene expression in primary mediastinal B-cell lymphoma (PMBL) and recently identified the protein as a secreted L-phenylalanine oxidase, physiologically expressed by myeloid cells, which inhibits T-cell proliferation in vitro. Here, we analyzed the pattern of IL4I1 protein express...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2008.380
更新日期:2009-05-01 00:00:00
abstract::Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecul...
journal_title:Leukemia
pub_type: 杂志文章,随机对照试验
doi:10.1038/s41375-018-0055-7
更新日期:2018-05-01 00:00:00
abstract::The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in t...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2017.257
更新日期:2018-02-01 00:00:00
abstract::To examine whether the percentage of myeloperoxidase (MPO)-positive blast cells is useful as a prognostic factor for acute myeloid leukemia (AML), cytochemical analysis of MPO was performed in 491 patients who were registered to the Japan Adult Leukemia Study Group-AML92 study. Patients were divided into two using the...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403010
更新日期:2003-08-01 00:00:00
abstract::Twenty new cases of acute lymphoblastic leukemia (ALL) with the dicentric chromosome dic(9;20)(p1113;q11) are presented. This chromosomal abnormality is difficult to identify from G-banding alone. It masquerades as monosomy 20 and is only accurately identified by fluorescence in situ hybridization (FISH). Monosomy 20 ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401654
更新日期:2000-02-01 00:00:00
abstract::We previously reported the fusion of the TEL gene to the Syk gene in myelodysplastic syndrome with t(9;12)(q22;p12). TEL-Syk fusion transformed interleukin-3 (IL-3)-dependent murine hematopoietic cell line BaF3 to growth factor independence. Here, we investigate the intracellular signal transduction of the stable tran...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403266
更新日期:2004-03-01 00:00:00
abstract::Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2016.260
更新日期:2017-03-01 00:00:00
abstract::To discriminate with molecular-cytogenetic resolution between 3q26.2 breakpoint, associated to various myeloproliferative disorders, and 3q27 breakpoint, recurrent in several types of non-Hodgkin lymphoma, we tested the feasibility of using a yeast artificial chromosome, YAC clone H10, mapped on 3q26.3. Fluorescent in...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1996-02-01 00:00:00
abstract::CK2 is a ubiquitously expressed, constitutively active Ser/Thr protein kinase, which is considered the most pleiotropic protein kinase in the human kinome. Such a pleiotropy explains the involvement of CK2 in many cellular events. However, its predominant roles are stimulation of cell growth and prevention of apoptosi...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/leu.2017.301
更新日期:2018-01-01 00:00:00